HRMY vs. BBIO, VTYX, AMPH, AKRO, VKTX, ABCL, HCM, NUVL, SLRN, and CVAC
Should you be buying Harmony Biosciences stock or one of its competitors? The main competitors of Harmony Biosciences include BridgeBio Pharma (BBIO), Ventyx Biosciences (VTYX), Amphastar Pharmaceuticals (AMPH), Akero Therapeutics (AKRO), Viking Therapeutics (VKTX), AbCellera Biologics (ABCL), HUTCHMED (HCM), Nuvalent (NUVL), Acelyrin (SLRN), and CureVac (CVAC). These companies are all part of the "pharmaceutical preparations" industry.
Harmony Biosciences vs.
BridgeBio Pharma (NASDAQ:BBIO) and Harmony Biosciences (NASDAQ:HRMY) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk, media sentiment and community ranking.
BridgeBio Pharma currently has a consensus price target of $26.63, indicating a potential upside of 93.64%. Harmony Biosciences has a consensus price target of $62.89, indicating a potential upside of 76.85%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Harmony Biosciences.
BridgeBio Pharma has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500.
Harmony Biosciences has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.
BridgeBio Pharma received 104 more outperform votes than Harmony Biosciences when rated by MarketBeat users. Likewise, 66.49% of users gave BridgeBio Pharma an outperform vote while only 46.34% of users gave Harmony Biosciences an outperform vote.
Harmony Biosciences has a net margin of 40.19% compared to BridgeBio Pharma's net margin of -546.34%. Harmony Biosciences' return on equity of 49.67% beat BridgeBio Pharma's return on equity.
96.5% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 84.8% of Harmony Biosciences shares are held by institutional investors. 29.6% of BridgeBio Pharma shares are held by insiders. Comparatively, 28.4% of Harmony Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Harmony Biosciences had 1 more articles in the media than BridgeBio Pharma. MarketBeat recorded 7 mentions for Harmony Biosciences and 6 mentions for BridgeBio Pharma. Harmony Biosciences' average media sentiment score of 1.20 beat BridgeBio Pharma's score of 0.91 indicating that Harmony Biosciences is being referred to more favorably in the news media.
Summary
BridgeBio Pharma and Harmony Biosciences tied by winning 9 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HRMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Harmony Biosciences Competitors List
Related Companies and Tools